UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more
Market Cap & Net Worth: UCB SA (UCBJF)
UCB SA (PINK:UCBJF) has a market capitalization of $32.36 Billion ($32.36 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #955 globally and #745 in its home market, demonstrating a -10.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UCB SA's stock price $170.00 by its total outstanding shares 190361362 (190.36 Million).
UCB SA Market Cap History: 2015 to 2025
UCB SA's market capitalization history from 2015 to 2025. Data shows growth from $14.10 Billion to $32.36 Billion (9.40% CAGR).
UCB SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UCB SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.18x
UCB SA's market cap is 4.18 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
20.78x
UCB SA's market cap is 20.78 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $10.25 Billion | $4.18 Billion | $520.00 Million | 2.45x | 19.71x |
| 2017 | $13.09 Billion | $4.53 Billion | $753.00 Million | 2.89x | 17.38x |
| 2018 | $14.41 Billion | $4.63 Billion | $800.00 Million | 3.11x | 18.01x |
| 2019 | $14.20 Billion | $4.91 Billion | $792.00 Million | 2.89x | 17.93x |
| 2020 | $19.14 Billion | $5.35 Billion | $732.00 Million | 3.58x | 26.14x |
| 2021 | $19.75 Billion | $5.78 Billion | $1.06 Billion | 3.42x | 18.66x |
| 2022 | $14.90 Billion | $5.52 Billion | $418.00 Million | 2.70x | 35.65x |
| 2023 | $16.39 Billion | $5.25 Billion | $343.00 Million | 3.12x | 47.79x |
| 2024 | $33.12 Billion | $6.15 Billion | $1.06 Billion | 5.38x | 31.10x |
| 2025 | $32.36 Billion | $7.74 Billion | $1.56 Billion | 4.18x | 20.78x |
Competitor Companies of UCBJF by Market Capitalization
Companies near UCB SA in the global market cap rankings as of March 18, 2026.
Key companies related to UCB SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
UCB SA Historical Marketcap From 2015 to 2025
Between 2015 and today, UCB SA's market cap moved from $14.10 Billion to $ 32.36 Billion, with a yearly change of 9.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $32.36 Billion | -2.30% |
| 2024 | $33.12 Billion | +102.06% |
| 2023 | $16.39 Billion | +10.00% |
| 2022 | $14.90 Billion | -24.53% |
| 2021 | $19.75 Billion | +3.18% |
| 2020 | $19.14 Billion | +34.77% |
| 2019 | $14.20 Billion | -1.47% |
| 2018 | $14.41 Billion | +10.14% |
| 2017 | $13.09 Billion | +27.64% |
| 2016 | $10.25 Billion | -27.28% |
| 2015 | $14.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of UCB SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.36 Billion USD |
| MoneyControl | $32.36 Billion USD |
| MarketWatch | $32.36 Billion USD |
| marketcap.company | $32.36 Billion USD |
| Reuters | $32.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.